Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies SA (DBVT) is a clinical-stage biopharmaceutical leader advancing epicutaneous immunotherapy (EPIT) through its innovative Viaskin platform, targeting food allergies with non-invasive precision. This page aggregates all essential updates on the company’s clinical progress, regulatory milestones, and strategic initiatives.
Investors and stakeholders gain centralized access to critical developments including phase trial results, FDA/EMA interactions, and partnership announcements. Each update is curated to provide actionable insights into DBVT’s pioneering work in allergy treatment while maintaining rigorous scientific accuracy.
Key coverage areas include Viaskin efficacy data, patent developments, and manufacturing scalability updates. The resource is designed to help users track the company’s progress from clinical research to potential commercialization without requiring cross-platform monitoring.
Bookmark this page for streamlined tracking of DBV Technologies’ advancements in redefining food allergy management through its unique skin-based immunotherapy approach.
DBV Technologies announced positive topline results from its Phase 3 EPITOPE trial evaluating Viaskin Peanut for peanut-allergic toddlers aged 1 to 3 years. The trial met its primary endpoint, with 67% of subjects in the treatment group achieving significant response criteria after 12 months, compared to 33.5% in the placebo group. Safety results were consistent with prior studies in older children, showing high compliance and a low discontinuation rate due to adverse events. DBV aims to analyze data for regulatory pathways, addressing a critical unmet need in this age group.
DBVT reported its total shares and voting rights as of April 30, 2022. The total number of shares stood at 55,095,537, while the total gross voting rights were also 55,095,537. After accounting for shares without voting rights, the total net voting rights amounted to 54,920,329. This information is compliant with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies held its Ordinary and Extraordinary General Meeting on May 12, 2022, where shareholders approved all proposed resolutions from the Board of Directors. The meeting, chaired by Michel de Rosen, confirmed the company's ongoing commitment to its strategic initiatives.
DBV Technologies is advancing Viaskin™, a proprietary platform for non-invasive immunotherapy aimed at treating food allergies, including clinical trials for Viaskin Peanut. For more information, visit the investors section of their website.
DBV Technologies has successfully completed the sale of American Depositary Shares (ADSs) raising $15.3 million through its At-The-Market program. The sale involved issuing 12,072,476 new ADSs, equivalent to 6,036,238 ordinary shares, resulting in a dilution of approximately 9.9% to existing shareholders. This capital increase will facilitate the company’s ongoing clinical trials for its Viaskin immunotherapy platform, aiming to enhance treatment options for food allergies. The delivery of new shares is scheduled for May 6, 2022.
DBV Technologies has announced an At-The-Market (ATM) program on Nasdaq, allowing it to raise up to $100 million through the sale of American Depositary Shares (ADS). This program, effective until July 16, 2024, will support the potential approval and launch of Viaskin™ Peanut and advance the development of other products. The plan involves selling up to 16,528,961 ordinary shares, potentially leading to a dilution of around 30%. Jefferies LLC will act as the sales agent, and the proceeds will also cover general corporate purposes.
DBV Technologies reported updates on the regulatory status of its lead product, Viaskin Peanut, following a Type C meeting granted by the FDA. This meeting is aimed at aligning on the new Phase 3 study protocol submitted as part of the FDA's briefing materials. Additionally, the company announced its first-quarter 2022 financial results, which were approved by the Board of Directors on April 29, 2022.
DBV Technologies announced a conference call for May 2, 2022, at 5:00 p.m. ET to discuss its first quarter 2022 financial results and corporate updates. The call will be available via teleconference and live webcast. DBV is focused on developing Viaskin™, a platform for epicutaneous immunotherapy aimed at treating food allergies, with ongoing trials for Viaskin Peanut. The company's shares are traded on Euronext and Nasdaq under the symbols DBV and DBVT, respectively.
DBV Technologies will hold its Ordinary and Extraordinary General Meeting on May 12, 2022, at 8:30 a.m. CEST in Montrouge, France. Preparatory documents are available on the company's website and via the French Bulletin des Annonces Légales Obligatoires. Shareholders can request documents until May 7, 2022, and the meeting will also be webcast live. DBV is focused on developing Viaskin™, an innovative platform for immunotherapy targeted at food allergies, with ongoing clinical trials for Viaskin Peanut.
The monthly report as of March 31, 2022, reveals that DBVT has a total of 55,095,537 shares outstanding. The total number of voting rights attached to these shares is 55,095,537, with a net total of 54,951,036 voting rights. This net total accounts for shares without voting rights. The report is compliant with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers and is intended for shareholders and market observers.
FAQ
What is the current stock price of Dbv Technologies S A (DBVT)?
What is the market cap of Dbv Technologies S A (DBVT)?
